Jazz Pharmaceuticals plc JAZZ
Jazz Pharmaceuticals plc is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with rare disease – often with limited or no therapeutic options. We have a diverse portfolio of medicines, including leading therapies addressing epilepsies, cancers and sleep disorders. Our patient-focused and science-driven approach powers pioneering R&D advancements across our robust pipeline of innovative therapeutics.
Our lead marketed products, listed below, are approved in countries around the world to improve patient care.
•Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution, a product approved by FDA in July 2020, and launched in the U.S. in November 2020 for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy, and also approved by FDA in August 2021 for the treatment of IH in adults and launched in the U.S. in November 2021. Xywav contains 92% less sodium than Xyrem®. Xywav is also approved in Canada for the treatment of cataplexy in patients with narcolepsy.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.27B | $4.07B | $3.83B | $3.66B | $3.09B | $2.36B | $2.16B | $1.89B | $1.62B | $1.49B |
| R&D | — | — | — | — | — | — | $299.7M | $226.6M | $198.4M | $162.3M |
| SG&A | $1.81B | $1.39B | $1.34B | $1.42B | $1.45B | $854.2M | $736.9M | $683.5M | $544.2M | $502.9M |
| Total operating expenses | $4.70B | $3.35B | $3.26B | $3.72B | $2.92B | $1.99B | $1.63B | $1.28B | $1.09B | $896.3M |
| Operating income | -$430.2M | $716.6M | $578.6M | -$65.5M | $170.3M | $378.1M | $532.4M | $614.8M | $528.8M | $591.7M |
| Pre-tax income | -$627.9M | $470.4M | $297.9M | -$372.8M | -$112.8M | $275.1M | $454.3M | $529.5M | $441.1M | $532.4M |
| Income tax | $272.4M | $91.4M | $119.9M | $158.6M | $216.1M | $33.5M | $73.2M | $80.2M | $47.7M | $135.2M |
| Net income | -$356.1M | $560.1M | $414.8M | -$224.1M | -$329.7M | $238.6M | $523.4M | $447.1M | $487.8M | $396.8M |
| EPS, basic | -5.84 | 9.06 | 6.55 | -3.58 | -5.52 | 4.28 | 9.22 | 7.45 | 8.13 | 6.56 |
| EPS, diluted | -5.84 | 8.65 | 6.10 | -3.58 | -5.52 | 4.22 | 9.09 | 7.30 | 7.96 | 6.41 |
| Shares, diluted (wtd. avg.) | $61.0M | $66.0M | $72.1M | $62.5M | $59.7M | $56.5M | $57.5M | $61.2M | $61.3M | $61.9M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $1.39B | $2.41B | $1.51B | $881.5M | $591.4M | $1.06B | $637.3M | $309.6M | $386.0M | $366.0M |
| Receivables | $830.7M | $716.8M | $705.8M | $651.5M | $563.4M | $396.5M | $356.0M | $263.8M | $224.1M | $234.2M |
| Inventory | $417.0M | $480.4M | $597.0M | $714.1M | $1.07B | $95.4M | $78.6M | $53.0M | $43.2M | $34.1M |
| Total current assets | $4.17B | $4.63B | $3.44B | $2.61B | $2.61B | $2.84B | $1.63B | $1.23B | $968.3M | $748.1M |
| Property, plant and equipment | — | — | — | — | — | $127.9M | $131.5M | $200.4M | $170.1M | $107.5M |
| Goodwill | $1.83B | $1.72B | $1.75B | $1.69B | $1.83B | $958.3M | $920.0M | $927.6M | $947.5M | $893.8M |
| Other intangibles | $4.43B | $4.76B | $5.42B | $5.79B | $7.15B | $2.20B | $2.44B | $2.73B | $2.98B | $3.01B |
| Total assets | $11.66B | $12.01B | $11.39B | $10.84B | $12.30B | $6.54B | $5.54B | $5.20B | $5.12B | $4.80B |
| Accounts payable | $122.1M | $77.9M | $102.8M | $90.8M | $100.3M | $26.9M | $45.7M | $40.6M | $24.4M | $22.4M |
| Short-term debt | $1.03B | $31.0M | $605.0M | $31.0M | $31.0M | $246.3M | $33.4M | $33.4M | $40.6M | $36.1M |
| Total current liabilities | $2.24B | $1.04B | $1.54B | $933.2M | $809.3M | $653.7M | $364.5M | $345.5M | $293.9M | $257.4M |
| Long-term debt | $4.33B | $6.08B | $5.11B | $5.69B | $6.02B | $1.85B | $1.57B | $1.56B | $1.54B | $1.99B |
| Retained earnings | $646.2M | $1.13B | $878.7M | $733.6M | $830.2M | $1.16B | $1.07B | $841.0M | $918.0M | $528.9M |
| Total equity | $4.32B | $4.09B | $3.74B | $3.09B | $3.97B | $3.66B | $3.11B | $2.76B | $2.71B | $1.88B |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.36B | $1.40B | $1.09B | $1.27B | $778.5M | $899.6M | $776.4M | $798.9M | $693.1M | $592.4M |
| Depreciation and amortisation | $41.6M | $32.8M | $30.4M | $30.3M | $26.7M | $18.7M | $15.3M | $15.2M | $13.1M | $11.8M |
| Stock-based compensation | $291.1M | $248.0M | $226.8M | $222.0M | $189.0M | $121.0M | $110.6M | $102.4M | $106.9M | $98.8M |
| Capital expenditure | $58.8M | $38.1M | $24.0M | $29.0M | $27.6M | $15.0M | $40.1M | $20.4M | $28.9M | $9.7M |
| Investing cash flow | -$1.51B | -$508.2M | -$163.1M | -$446.2M | -$5.21B | -$1.01B | -$155.3M | -$394.5M | -$268.9M | -$1.75B |
| Financing cash flow | -$873.4M | $20.5M | -$305.3M | -$529.5M | $3.97B | $528.1M | -$293.7M | -$479.1M | -$409.1M | $541.0M |
| Buybacks | $125.0M | $311.4M | $269.8M | $54.0K | $0 | $146.5M | $301.4M | $523.7M | $98.8M | $278.3M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001232524-26-000029.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |